Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | PABPC1 | P11940 | 5/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10404298 | 1.00 | KMT2A (0.67) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL3761569 | 0.86 | KMT2A (0.68) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL50309 | 0.86 | KMT2A (0.67) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL2748441 | 0.85 | KMT2A (0.58) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL29764668 | 0.85 | KMT2A (0.58) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL7886661 | 0.85 | KMT2A (0.62) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL22773569 | 0.84 | KMT2A (0.65) | KMT2AMEN1MAPTKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL38658753 | 0.84 | KMT2A (0.66) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL590618 | 0.83 | KMT2A (0.61) | KMT2AMEN1MAPTKDM4ERAB9A | |
| SCHEMBL12049704 | 0.83 | KMT2A (0.68) | KMT2AMEN1MAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | F2RL3, PARP14, F2R | KMT2A 897/4885MEN1 871/4885MAPT 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.